tbuckley/cabot-search huggingface dataset:
Oral Arginine Increases Erythrocyte Glutathione Levels in Sickle Cell Disease: Implications for Pulmonary Hypertension.
Authors: Claudia R. Morris, Jung Suh, Elliott P. Vichinsky, Elizabeth S. Klings, Martin H. Steinberg, Mark Shigenaga, Bruce N. Ames, Mark T. Gladwin, Gregory J. Kato
Journal: Blood (2006)
Simultaneous Assay of Agonist-Induced Endogenous and Non-Radioactive Isotopic Serotonin Secretion from Small Numbers of Human Platelets By Mass Spectrometry
Authors: Xin Yi, Zhiyun Cao, Ina Sandeli, Edward KY Leung, Kiang-Teck Jerry Yeo, Jonathan L. Miller
Journal: Blood (2015)
Depletion of the Intracellular Akt Kinase, and Its Downstream Signaling, Mediates Synergy between the Proteasome Inhibitor MG-132 and the Heat Shock Protein 90 Inhibitor 17-AAG in the Multiple Myeloma Cell Line U266.
Authors: Christopher Maisel, Nizar Bahlis, Yanling Miao, Lili Liu, Stanton Gerson
Journal: Blood (2004)
Novel Treatment of Burkitt Lymphoma with Dose-Adjusted EPOCH-Rituximab: Preliminary Results Showing Excellent Outcome.
Authors: Kieron Dunleavy, Stefania Pittaluga, John Janik, Nicole Grant, Margaret Shovlin, Richard Little, Robert Yarchoan, Seth Steinberg, Elaine S. Jaffe, Wyndham H. Wilson
Journal: Blood (2006)
Favorable Outcome of Children with Acute Megakaryoblastic Leukemia Treated with the AIEOP AML 2002/01 Protocol
Authors: Franco Locatelli, Maria Caterina Putti, Andrea Pession, Franca Fagioli, Giuseppe Menna, Concetta Micalizzi, Carmelo Rizzari, Sergio Rutella, Andrea Biondi, Barbara Buldini, Riccardo Masetti, Giuseppe Basso
Journal: Blood (2012)
Exome Sequencing to Define a Genetic Signature of Plasma Cells in Systemic AL Amyloidosis
Authors: Eileen M Boyle, Brian A Walker, Dorota Rowczienio, Christopher P Wardell, Alexander Murison, Aneta Mikulasova, Sajitha Sachchithanantham, Anna Baginska, Shameem Mahmood, Julian D Gillmore, Helen J Lachmann, Philip N Hawkins, Xavier Leleu, Faith E Davies, Gareth J. Morgan, Ashutosh Wechalekar
Journal: Blood (2014)
Interest of Early Determination of Bone Marrow MRD by a Sensitive 6-Color Flow Cytometry in the Evaluation of Response: The Experience of the CLL2007FMP, An Intergroup Phase III Randomized Multicentric Trial Comparing Fludarabine Cyclophosphamide (FC) and Rituximab (FCR) Versus FC and MabCampath (FCCam) in Previously Untreated B-Chronic Lymphocytic Leukemia Patients
Authors: Remi Letestu, Stéphane Leprêtre, Christine Arnoulet, Lucile Baseggio, Lydia Campos, Bernard Chatelain, Bernard Drenou, Marie-Christine Jacob, Eric Legac, Magali Le Garff-Tavernier, Nelly Robillard, Michel Ticchioni, Roselyne Delepine, Vincent Levy, Sandrine Katsahian, Veronique Leblond, Florence Cymbalista, Pierre Feugier
Journal: Blood (2011)
A customizable microfluidic platform for medium-throughput modeling of neuromuscular circuits
Authors: Jessica Bellmann, Ruchi Y. Goswami, Salvatore Girardo, Nelly Rein, Zohreh Hosseinzadeh, Michael R. Hicks, Volker Busskamp, April D. Pyle, Carsten Werner, Jared Sterneckert
Journal: Biomaterials (2019)

Neuromuscular circuits (NMCs) are vital for voluntary movement, and effective models of NMCs are needed to understand the pathogenesis of, as well as to identify effective treatments for, multiple diseases, including Duchenne's muscular dystrophy and amyotrophic lateral sclerosis. Microfluidics are ideal for recapitulating the central and peripheral compartments of NMCs, but myotubes often detach before functional NMCs are formed. In addition, microfluidic systems are often limited to a single experimental unit, which significantly limits their application in disease modeling and drug discovery. Here, we developed a microfluidic platform (MFP) containing over 100 experimental units, making it suitable for medium-throughput applications. To overcome detachment, we incorporated a reactive polymer surface allowing customization of the environment to culture different cell types. Using this approach, we identified conditions that enable long-term co-culture of human motor neurons and myotubes differentiated from human induced pluripotent stem cells inside our MFP. Optogenetics demonstrated the formation of functional NMCs. Furthermore, we developed a novel application of the rabies tracing assay to efficiently identify NMCs in our MFP. Therefore, our MFP enables large-scale generation and quantification of functional NMCs for disease modeling and pharmacological drug targeting.
Progressive but Previously Untreated CLL Patients with Greater Array CGH Complexity Exhibit A Less Durable Response to Chemoimmunotherapy
Authors: Neil E. Kay, Jeanette Eckel Passow, Esteban Braggio, Scott Van Wier, Tait Shanafelt, Daniel L. Van Dyke, Diane F. Jelinek, Renee Tschumper, Thomas J. Kipps, John C. Byrd, Rafael Fonseca
Journal: Blood (2010)
Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome with a Reduced Intensity Conditioning Regimen Consisting of Intravenous Busulfan, Fludarabine, and 400 Cgy Total Body Irradiation.
Authors: Sung Eun Lee, Yoo Jin Kim, Seok Goo Cho, Byung Sik Cho, Ki-Seong Eom, Hee Je Kim, Seok Lee, Chang-Ki Min, Dong Wook Kim, Jong Wook Lee, Woo Sung Min, Chong Won Park, Chun Choo Kim
Journal: Blood (2009)
Idarucizumab, a Specific Antidote for Dabigatran: Immediate, Complete and Sustained Reversal of Dabigatran Induced Anticoagulation in Elderly and Renally Impaired Subjects
Authors: Stephan Glund, Joachim Stangier, Michael Schmohl, Viktoria Moschetti, Wouter Haazen, Marina De Smet, Dietmar Gansser, Stephen Norris, Benjamin Lang, Paul Reilly
Journal: Blood (2014)
PEGylation or Polysialylation Reduces FVIII Binding to LRP Resulting in Prolonged Half-Life in Murine Models.
Authors: Hanspeter Rottensteiner, Peter L. Turecek, Rona Pendu, Alexander B. Meijer, Peter Lenting, Koen Mertens, Eva-Maria Muchitsch, Hartmut Ehrlich, Hans Peter Schwarz
Journal: Blood (2007)
Lenalidomide Plus Low-Dose Dexamethasone (Ld): Superior One and Two Year Survival Regardless of Age Compared to Lenalidomide Plus High-Dose Dexamethasone (LD)
Authors: David H. Vesole, Susanna Jacobus, S. Vincent Rajkumar, Rafat Abonour, Natalie Scott Callander, Philip R. Greipp, Rafael Fonseca, Michael S Katz, David Samuel diCapua Siegel
Journal: Blood (2010)
A Phase 1, Dose-Escalation Study of Topical Sodium Nitrite in Patients with Sickle Cell Anemia and Leg Ulcers
Authors: Caterina P. Minniti, Yuen Yi Hon, Alexander Gorbach, Kara M Delaney, Dihua Xu, Nitin Malik, Jordan Maivelett, Enrico M Novelli, Sophia Lanzkron, Gregory J. Kato
Journal: Blood (2012)
A Double-Blind, Multicentre, Randomised, Placebo-Controlled Study to Assess the Efficacy, Safety and Tolerability of Prophylactic Liposomal Amphotericin B (AmBisome®) for the Prevention of Invasive Fungal Infections in Subjects Receiving Remission-Induction Chemotherapy for Acute Lymphoblastic Leukaemia (AmBiGuard trial)
Authors: Oliver Cornely, Thibaut Leguay, Johan Maertens, Carlo Castagnola, Achilles Anagnostopoulos, Bernadino Allione, Claus Peter Heussel, J Peter Donnelly, Samir G. Agrawal, Will Garner, Catherine Simcock, Michael J. Hawkins, Nicola Goekbuget
Journal: Blood (2014)
Lymphoblasts Produce a Lysosomal Protease That Rapidly Degrades L-Asparaginase - Implications for Therapy in Childhood Acute Lymphoblastic Leukemia.
Authors: Naina Patel, Shekhar Krishnan, Marc N. Offman, Cathy X. Moss, Hany Ariffin, Fred W. vanDelft, Olga Yiannikouris, Carly Leighton, Seema Alexander, Mark Holland, Doaa Khater, Ji Zhong Liu, Monika Essink, Paul Bates, Colin Watts, Vaskar Saha
Journal: Blood (2007)
Fetomaternal Microchimerism Is Associated with Better Outcome in Haploidentical Hematopoietic Stem Cell Transplantation
Authors: Anne Kruchen, Tanja Stahl, Friederike Gieseke, Thomas MC Binder, Zakir Oezcan, Roland Meisel, Hermann Kreyenberg, Peter Bader, Bernd Gruhn, Johann Greil, Matthias Pfeiffer, Michaela Doering, Rupert Handgretinger, Boris Fehse, Ingo Mueller
Journal: Blood (2014)
Bystander secretion of hsp70 provides adjuvant effect throughout DC-NK interaction
Authors: Chiara Massa, Mario P. Colombo
Journal: Cancer Research (2005)

4246  Tumor derived heat shock proteins (HSP) can induce antigen specific immune response. Studies performed with purified proteins suggest that HSP interact with dendritic cells (DC) providing them with chaperoned antigens and danger signals that allow their maturation and, consequently, proper T cell activation. To dissect the chaperone and adjuvant activity of hsp70, independently from possible contaminations that might occur during protein purification, we modified murine inducible hsp70 into a secreted protein and engineered a transformed fibroblast cell line, F1aFR, to constitutively secrete hsp70 into the culture supernatant. DC incubated with supernatant from hsp70-transfected F1aFR cells bind the protein and, after its internalization, cross-present F1aFR derived peptides to specific T cell lines in vitro. Thus, despite genetic manipulation, secreted hsp70 retains the chaperone activity and enhances tumor immunogenicity in vivo as evaluated by reduced tumor growth and by superior CTL response against F1aFR antigens. The danger activity of secreted hsp70 varies according to the source of DC. Whereas both bone marrow and spleen derived DC show increased uptake of either fluorescent beads or apoptotic cells in the presence of hsp70-containing supernatant, only splenic DC display a small increase in the expression of CD86 costimulatory molecule. The bystander adjuvant activity of hsp70 on DC antigen uptake was confirmed in vivo. Mice were injected with CFSE-labeled C26 cells together with bystander fibroblast secreting or not hsp70. The percentage of CFSE+ DC in the draining lymph node was significantly higher in lymph node from mice receiving fibroblasts secreting hsp70. Accordingly, an enhanced CTL response against C26-derived epitopes was obtained when bystander cells secreting hsp70 where part of the cellular vaccine. However, the almost similar efficacy of hsp70 to induce CTL against either chaperoned or bystander antigens cannot be translated in a therapeutic setting. Mice bearing C26aFR lung metastasis are better cured by a vaccine in which hsp70 is secreted directly by the antigen cell source (F1hsp70aFR) rather than by a bystander cell (F1aFR + F1hsp70). The bystander but not chaperone activity of hsp70 was then lost in mice depleted of NK cells. While uncoupling the danger signal from the chaperone activity of hsp70 slightly reduce vaccine efficacy, the results point to the possibility of using a bystander cells secreting soluble HSP to be admixed with autologous tumor, a practical way to create cellular cancer vaccines.
Randomised Intergroup Trial of First line Treatment for young Low-Risk Patients (&lt;61 years) with Diffuse Large B-Cell Non-Hodgkin's Lymphoma (DLBCL) with a CHOP-like Regimen with or without the Anti-CD20 Antibody Rituximab – 6-Year Follow-up of the Mint Study of the Mabthera International Trial (MInT) Group
Authors: Michael Pfreundschuh, Evelyn Kuhnt, Lorenz Trümper, Anders Osterborg, Marek Trneny, Lois Shepherd, Devinder S Gill, Jan Walewski, Ruth Pettengell, Ulrich Jäger, Pier Luigi Zinzani, Ofer Shpilberg, Stein Kvaloy, Mads Hansen, Rolf Stahel, Noel Milpied, Armando Lopez-Guillermo, Sandra Grass, Niels Murawski, Viola Pöschel, Markus Löffler
Journal: Blood (2010)
Childbirth: one in three women in low and middle income countries reports being mistreated
Authors: Elisabeth Mahase
Journal: BMJ (2019)

Over a third of women in four low and middle income countries have experienced mistreatment around the time of childbirth, a study has found.1

The research, led by the World Health Organization, included women aged 15 or over at 12 health facilities in Ghana, Guinea, Myanmar, and Nigeria from September 2016 to January 2018.

In many cases women had experienced physical or verbal abuse and or not been asked for consent for procedures such as caesarean section. In some cases women or their babies had been detained in facilities because they were unable to pay the healthcare bill.

The findings echo those of a …
Aberrant mechanosensing in injured intervertebral discs as a result of boundary-constraint disruption and residual-strain loss
Authors: Edward D. Bonnevie, Sarah E. Gullbrand, Beth G. Ashinsky, Tonia K. Tsinman, Dawn M. Elliott, Pen-hsiu Grace Chao, Harvey E. Smith, Robert L. Mauck
Journal: Nature Biomedical Engineering (2019)
High Dose Chemotherapy (HD CHT) Followed by Autologous PBPC Transplant in Elderly ANLL Patients.
Authors: Debora Capelli, Emanuela Troiani, Giancarlo Discepoli, Antonella Poloni, Mauro Montanari, Massimo Catarini, Riccardo Centurioni, Francesco Alesiani, Marino Brunori, Moira Lucesole, Pietro Leoni, Attilio Olivieri
Journal: Blood (2004)
Tubular Damage Is Present In Patients With MGUS and Asymptomatic Multiple Myeloma Even In The Absence Of Impaired Estimated Glomerular Filtration Rate; Alterations Of Neutrophil Gelatinase-Associated Lipocalin and Cystatin-C In Myeloma Patients Post IMiD- and Bortezomib-Based Regimens
Authors: Evangelos Terpos, Dimitrios Christoulas, Efstathios Kastritis, Gerasimos-Petros Papassotiriou, Filia Apostolakou, Alexandra Margeli, Nikolaos Kanellias, Evangelos Eleutherakis-Papaiakovou, Ioannis Papassotiriou, Meletios A. Dimopoulos
Journal: Blood (2013)
Impact of Eltrombopag on Expansion of Clones with Somatic Mutations in Refractory Aplastic Anemia
Authors: Bhumika J. Patel, Bartlomiej Przychodzen, Michael J. Clemente, Cassandra M. Hirsch, Tomas Radivoyevitch, Swapna Thota, Aziz Nazha, Hetty E. Carraway, Mikkael A. Sekeres, Jaroslaw P. Maciejewski
Journal: Blood (2015)
Cytogenetic Predictors of Response to Lenalidomide In Myeloid Malignancies without Del(5q)
Authors: Yuka Sugimoto, Mikkael A. Sekeres, Hideki Makishima, Christine L. O'Keefe, Kathryn Guinta, Manuel Afable, Kathy Rocha McGraw, Alan F. List, Jaroslaw Maciejewski
Journal: Blood (2010)
Rare Pre-Existing MDS Subclones Contribute to Secondary AML Progression
Authors: Eric J. Duncavage, Meagan A. Jacoby, Chris Miller, Gue Su Chang, Jin Shao, Kevin Elliot, Catrina Fronick, Michelle O'Laughlin, Robert Fulton, Richard K Wilson, Timothy A. Graubert, Matthew J. Walter
Journal: Blood (2016)
Richter Syndrome (RS): Genome-Wide Promoter Methylation Profile Differs From De Novo Diffuse Large B-Cell Lymphoma (DLBCL) and Affects Genes Involved in Stem-Cell Maintenance and TP53 Pathway
Authors: Davide Rossi, Andrea Rinaldi, Ivo Kwee, Luca Arcaini, Marco Lucioni, Valter Gattei, Roberto Marasca, Francesco Forconi, Francoise Berger, Sergio Cogliatti, Emanuele Zucca, Gianluca Gaidano, Francesco Bertoni
Journal: Blood (2011)
Lenalidomide Maintenance Does Not Negatively Impact Overall and Progression Free Survival Using Lenalidomide-Based Regimens for Multiple Myeloma in First Relapse
Authors: Hannah Cherniawsky, Zack M. Breckenridge, Irwindeep Sandhu, Michael P. Chu, Joanne D. Hewitt, Ismail Ismail, Andrew R Belch, Linda M. Pilarski, Tatiana Nikitina, Christopher P. Venner
Journal: Blood (2018)
The Risk of Vascular and Thromboembolic Events Is Increased In Young Low-Risk Germ Cell Cancer Patients by Cisplatin Containing Chemotherapy
Authors: Leticia M Solari, Kathrin Dollinger, Jürgen Heinz, Heike Reinhardt, Susanne Rohdenburg, Monika Engelhardt, Cornelius F. Waller
Journal: Blood (2010)
The clinicopathological features of long-term survivors of metastatic gastric cancer
Authors: Kenji Ina, Ryuichi Furuta, Megumi Kabeya, Satoshi Hibi, Shu Yuasa, Yuko Kato, Takashi Yoshida, Takae Kataoka, Satoshi Kayukawa
Journal: Annals of Oncology (2019)
The Bruton Tyrosine Kinase (Btk) Inhibitor ACP-196: Marked Activity in Relapsed/Refractory CLL with a Favorable Safety Profile
Authors: John C. Byrd, William Wierda, Jeffrey Jones, Susan O'Brien, Jennifer R. Brown, Anna Schuh, Peter Hillmen, Deborah M. Stephens, Paolo Ghia, Steve Devereux, Jorge M. Chaves, Jacqueline C. Barrientos, Min Hui Wang, Jane Huang, Todd Covey, Tasheda Navarro, Wayne Rothbaum, Raquel Izumi, Ahmed Hamdy, Richard R. Furman
Journal: Blood (2015)
Identification of CAR As a Novel Mediator of Erythroid Differentiation and Migration That Is Specifically Downregulated in Erythropoietic Progenitor Cells in Patients with MDS
Authors: Karin Bauer, Sigrid Machherndl-Spandl, Susanne Suessner, Martin Danzer, Johannes Pröll, Jeroen Lauf, Gregor Eisenwort, Wolfgang R. Sperr, Hans-Ulrich Klein, Gregor Hoermann, Norman Häfner, Marie Bene, Uwe Platzbecker, Ansgar Weltermann, Christian Gabriel, Ulrich Germing, Peter Bettelheim, Peter Valent
Journal: Blood (2014)
Mutational Concordance from Diagnosis and Relapse in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group
Authors: Katherine Tarlock, Todd M Cooper, Todd A. Alonzo, Robert Gerbing, Jessica Pollard, Richard Aplenc, E. Anders Kolb, Alan S. Gamis, Soheil Meshinchi
Journal: Blood (2016)
LIGHT (TNFSF14) Increases Survival and Proliferation of Human Bone Marrow-Derived Mesenchymal Stem Cells Via LTβR
Authors: Hawk Kim, Sook-Kyoung Heo, Eui-Kyu Noh, Gi-Dong Gwon, Jae-Cheol Jo, Yunsuk Choi, Jinny Park
Journal: Blood (2016)
Image Gallery: Widespread erosive tinea corporis mimicking autoimmune bullous dermatoses in a patient with lung cancer
Authors: W.‐C. Shen, N.‐F. Chang Liao, P.‐Y. Wu
Journal: British Journal of Dermatology (2019)

Funding sources: none. Conflicts of interest: none to declare. Dear Editor, A 50‐year‐old woman with right lung adenocarcinoma developed painful erosions with annular pustules (a) 2 weeks after chemotherapy with pemetrexed, carboplatin and bevacizumab. Skin biopsy revealed intracorneal pustules with fungal hyphae (b, haematoxylin and eosin stain, 40 × magnification) with Grocott methenamine silver stain positive (c, 200 × magnification). Direct immunofluorescence was negative. Both skin and pus cultures grew Trichophyton mentagrophytes. The lesions had cleared with postinflammatory hyper‐ and hypopigmentation after treatment with griseofulvin (250 mg twice daily for 1 month) (d) and had not recurred within 2 months. Tinea infection rarely causes widespread erosions or annular pustular patches in patients who are immunosuppressed or who are bedridden.1,2 These unusual presentations may mimic more serious dermatoses and warrant investigation. ...
Response to: ‘Medications associated with fracture risk in patients with rheumatoid arthritis’ by Chen <i>et al</i>
Authors: Gulsen Ozen, Kaleb Michaud
Journal: Annals of the Rheumatic Diseases (2019)

Response to: 'Medications associated with fracture risk in patients with rheumatoid arthritis' by Chen et alWe appreciate the interest shown by Dr Chen 1 concerning our recent study on medications associated with fracture risk in patients with rheumatoid arthritis (RA). 2 We would like to clarify some issues Chen et al indicated.First, we agree that osteoporotic fractures are more common in patients with inflammatory diseases.However, in our study, we excluded all patients with prevalent fractures to estimate the risk related to new fractures.Our study only shows the osteoporosis site fracture incidence in patients with RA.As we indicated in our manuscript, the incidence rate of osteoporotic fractures in our cohort is similar to a recent meta-analysis of 25 cohort studies in patients with RA. 3 Second, it is possible that high-intensity statin regimens may prevent fractures better than moderate-intensity ones especially if the protective effects are assumed to be due to anti-inflammatory properties of statins.Moreover, as Chen et al indicate, some antihypertensives may have protective effects on osteoporotic fracture risk.However, the only randomised controlled trial for this association is with thiazide diuretics 4 5 of which effect is also more biologically plausible compared with other antihypertensives. 6The fracture risk change with high-intensity statins and antihypertensives should be investigated further in patients with RA.Lastly, we appreciate the comment about our outcome-only osteoporosis site fractures.It is well-known that patients with RA have increased fall risk, which can also cause fractures.Unfortunately, we do not have any data for the level of trauma and fall risk other than disability scores.Regardless, we believe that including all types of fractures would make our outcome very heterogeneous.A significant trauma could cause a fracture in any patient even in the absence of risk factors.We are planning to collect more data regarding fall risk to better assess the fracture risk in our cohort.
Enhanced Cytotoxicity of Monoclonal Antibody SGN-40 and Immunomodulatory Drug IMiD3 Against Human Multiple Myeloma.
Authors: Yu-Tzu Tai, Laurence Catley, Xian-Feng Li, Makoto Hamasaki, Klaus Podar, Teru Hideshima, Dharminder Chauhan, Robert Schlossman, Paul Richardson, Steven P. Streon, Nikhil C. Munshi, Kenneth C. Anderson
Journal: Blood (2004)
Down-Regulation of Protein C Pathway Associated with Increased Inflammation in Patients with Implanted Ventricular Assist Devices As a Potential Cause of Pump Thrombosis
Authors: Tania Torres, Jeanine M. Walenga, Walter Jeske, Vicki Escalante, Erin Coglianese, Jeffrey Schwartz, Mamdouh Bakhos
Journal: Blood (2016)
A Pilot Study of Pomalidomide and Dexamethasone in Previously Treated Light Chain Amyloidosis Patients.
Authors: Angela Dispenzieri, Morie A Gertz, Suzanne R. Hayman, Francis Buadi, Shaji Kumar, Craig B. Reeder, Steven R. Zeldenrust, S.Vincent Rajkumar, Kristen Detweiler-Short, John A. Lust, Thomas E Witzig, Philip R. Greipp, Stephen J. Russell, David Dingli, Jacob Allred, Kristina Laumann, Melanie Ann Thompson, Rafael Fonseca, A. Keith Stewart, P. Leif Bergsagel, Joseph R. Mikhael, Vivek Roy, Robert Kyle, Martha Q. Lacy
Journal: Blood (2009)
Combined Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) Is Active for Relapsed and Refractory Patients with CLL.
Authors: William Wierda, Stefan Faderl, Susan O’Brien, Jorge Cortes, Alessandra Ferrajoli, Francis Giles, Michael Andreff, Charles Koller, Hagop Kantarjian, Michael Keating
Journal: Blood (2004)
Transcriptional Silencing of the Wnt-Antagonist Dickkopf-1 (DKK1) by Promoter Methylation Unleashes Aberrant Wnt Signaling In Advanced Multiple Myeloma
Authors: Kinga A Kocemba, Richard W Groen, Harmen van Andel, Karene Mahtouk, Marie Jose Kersten, Marcel Spaargaren, Steven T Pals
Journal: Blood (2010)
Weekly Carfilzomib with Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma: Updated Results from the Phase 1/2 Study Champion-1 (NCT01677858)
Authors: James Berenson, Alan Cartmell, Roger Lyons, Wael Harb, Dimitrios Tzachanis, Richy Agajanian, Ralph V. Boccia, Morton Coleman, Robert A. Moss, Robert M. Rifkin, Marco Schupp, Sandra Dixon, Ying Ou, Janet Anderl, Jesus G. Berdeja
Journal: Blood (2015)
Recombinant Activated Factor VII (rFVIIa) in the Treatment of Non-Hemophilia Patients: Physician Underreporting of Thromboembolic Adverse Events.
Authors: Cyrus C. Hsia, Joanna H. Zurawska, Michael Z.Y. Tong, Kathleen Eckert, Vivian C. McAlister, Ian H. Chin-Yee
Journal: Blood (2007)
p27 Is Mislocalized to the Cytoplasm by BCR-ABL In a Kinase-Independent Manner and Contributes to Leukemogenesis
Authors: Anupriya Agarwal, Ryan J Meckenzie, Thomas O'Hare, Kavin B Vasudevan, Dorian H LaTocha, Marc M Loriaux, Eduardo Firpo, James M Roberts, Brian J Druker, Michael W Deininger
Journal: Blood (2010)
Elotuzumab In Combination with Bortezomib In Patients with Relapsed/Refractory Multiple Myeloma: Updated Results of a Phase 1 Study
Authors: Andrzej J Jakubowiak, Don M Benson, William Bensinger, David S Siegel, Todd M Zimmerman, Ann Mohrbacher, Paul G Richardson, Daniel EH Afar, Anil K Singhal, Kenneth C Anderson
Journal: Blood (2010)